Evelo Biosciences Stock News

Evelo Biosciences Inc (EVLO) shares closed today at 0.7% above its 52 week low of $5.55, giving the company a market cap of $310M. The stock is currently down 4.3% year-to-date, down 58.2% over the past 12 months, and down 64.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 10.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 41.7% The company's stock price performance over the past 12 months lags the peer average by 90.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Evelo Biosciences Inc (EVLO) shares closed today 15.1% lower than it did at the end of yesterday. The stock is currently down 43.8% year-to-date, down 36.8% over the past 12 months, and down 58.2% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $8.24 and as low as $6.69 this week.Shares closed 65.9% below its 52-week high and 18.3% above its 52-week low.Trading volume this week was 75.3% lower than the 10-day average and 67.2% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 52.9% The company's stock price performance over the past 12 months lags the peer average by 22.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that the Company has been added to the NASDAQ Biotechnology Index ® (Nasdaq: NBI), effective prior to market open on December 20, 2021.

Goldman Sachs Group Inc. boosted its position in shares of Evelo Biosciences, Inc. (NASDAQ:EVLO) by 90.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 26,779 shares of the companys stock after purchasing an additional 12,716 shares during the quarter. Goldman Sachs Group Inc.s holdings []

In last trading session, Evelo Biosciences Inc. (NASDAQ:EVLO) saw 0.3 million shares changing hands with its beta currently measuring 1.57. Companys recent per share price level of $8.25 trading at -$0.16 or -1.90% at ring of the bell on the day assigns it a market valuation of $436.92M. That closing price of EVLOs stock is Evelo Biosciences Inc. (NASDAQ:EVLO) Down -3.06% Over A Week, Now Can The Stock Hit Well Above -$0.26? Read More »

California State Teachers Retirement System lifted its stake in shares of Evelo Biosciences, Inc. (NASDAQ:EVLO) by 20.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,923 shares of the companys stock after acquiring an additional 7,188 shares during the quarter. California State Teachers Retirement [] The post California State Teachers Retirement System Boosts Stock Holdings in Evelo Biosciences, Inc. (NASDAQ:EVLO) appeared first on ETF Daily News .

Marshall Wace LLP reduced its holdings in Evelo Biosciences, Inc. (NASDAQ:EVLO) by 58.2% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 62,602 shares of the companys stock after selling 87,324 shares during the period. Marshall Wace LLPs holdings in Evelo Biosciences were worth $861,000 at the end of the most recent reporting period. []

AQR Capital Management LLC cut its holdings in Evelo Biosciences, Inc. (NASDAQ:EVLO) by 72.6% in the second quarter, HoldingsChannel reports. The firm owned 13,092 shares of the companys stock after selling 34,616 shares during the period. AQR Capital Management LLCs holdings in Evelo Biosciences were worth $180,000 as of its most recent SEC filing. A []

Northern Trust Corp lifted its holdings in shares of Evelo Biosciences, Inc. (NASDAQ:EVLO) by 26.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 322,651 shares of the companys stock after purchasing an additional 67,771 shares during the period. Northern []

Zacks Investment Research upgraded shares of Evelo Biosciences (NASDAQ:EVLO) from a sell rating to a hold rating in a report released on Monday, Zacks.com reports. According to Zacks, Evelo Biosciences, Inc. operates as a bio-technology company. It develops therapies for the treatment of the gut-body network. The company also offers treatment for cancer and inflammatory []

Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q3 2021 Results - Earnings Call Transcript

The consensus price target hints at a 164.5% upside potential for Evelo Biosciences, Inc. (EVLO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e

–Data suggest SINTAX™ medicine may overcome blood-brain barrier limitations to anti-inflammatory drug delivery– –EDP1867 reduced disease severity and incidence of relapse in murine model of mu